Press Releases

Date Title
October 9, 2020 Progenity to Present Precision Medicine Abstracts at American College of Gastroenterology (ACG) Virtual Annual Meeting in October
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, is pleased to announce that two abstracts related to Progenity’s ingestible technologies
October 1, 2020 Progenity Supports the Preeclampsia Foundation Call to Action to Accelerate Development and Adoption of Biomarker Tests for Preeclampsia
SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced support for the Preeclampsia Foundation’s recent call to action advocating
September 18, 2020 Progenity Announces Addition to Russell 2000® Index
SAN DIEGO, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will be added to the Russell 2000 ®  Index, effective when the U.S.
September 2, 2020 Progenity to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of
August 21, 2020 Progenity Commends New Recommendations from ACOG and SMFM Supporting Non-Invasive Prenatal Testing (NIPT) for All Pregnancies
SAN DIEGO, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products including NIPT, commends the recent guideline update from the American College of
August 13, 2020 Progenity Provides Corporate Updates and Reports Second Quarter 2020 Financial Results
Completed initial public offering raising gross proceeds of $100M Reported 75 thousand tests in the second quarter, showing resiliency of business during COVID‑19 pandemic Signed first precision medicine program pharma deal Management will host conference call and webcast today at 4:30 p.m.
August 6, 2020 Progenity to Report Second Quarter 2020 Financial Results
SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report second quarter 2020 financial results on Thursday,
July 23, 2020 Progenity Reaches Resolution with Government Related to Past Business, Promotional, and Billing Practices
The Company has established and continues to make significant investments in industry-leading compliance protocols and reporting standards SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company focused on providing complex molecular and specialized
June 19, 2020 Progenity Announces Pricing of Initial Public Offering
SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc . (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the pricing of its initial public offering of 6,666,667 shares of common
May 27, 2020 Progenity Shares Posters Identifying Key Factors for Clinical Decision Making
The four posters were released for the 2020 American College of Medical Genetics and Genomics’ (ACMG) Annual Clinical Genetics Meeting. SAN DIEGO, May 27, 2020— Progenity, a biotechnology company with an established track record of success in developing and commercializing molecular testing
Displaying 1 - 10 of 33